CS logo
small CS logo
Fondazione del Piemonte per l'Oncologia IRCC Candiolo

Candiolo, Torino, Italy
Specialized hospital in Italy
SP142 km 3,95, 10060 Candiolo TO

About Fondazione del Piemonte per l'Oncologia IRCC Candiolo


"L’istituto di Candiolo IRCCS è un centro specializzato nel trattamento delle patologie oncologiche, per alcune delle quali si configura come riferimento internazionale, ed è inserito nella Rete Oncologica del Piemonte-Valle d’Aosta. E’ il primo Istituto di Ricovero e Cura a Carattere Scientifico del Piemonte riconosciuto dal Ministero della Sanità."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
19
Italian Sarcoma Group
14
Fondazione del Piemonte per l'Oncologia
13
Eli Lilly and Company
6
Incyte Corporation
6
EMD Serono Research & Development Institute, Inc.
4
National Cancer Institute, Naples
4
Pfizer
4
Fondazione Italiana Linfomi ONLUS
2
Genentech, Inc.
2
Grupo Espanol de Investigacion en Sarcomas
2
Total Rows: 35

Clinical Trials at Fondazione del Piemonte per l'Oncologia IRCC Candiolo


During the past decade, Fondazione del Piemonte per l'Oncologia IRCC Candiolo conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 26 clinical trials were completed, i.e. on average, 37.1% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 17 clinical trials were completed. i.e. 70.8% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years779999881313121288441100113344556633Started TrialsCompleted Trails20152016201720182019202020212022051015
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
2006-09-04
2011-05-26
Completed
545
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
2008-02-12
2018-11-23
Completed
808
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
2008-10-16
2029-09-20
Recruiting
720
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
2004-01-19
2011-07-21
Completed
234
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
2007-08-30
2016-05-31
Completed
3,942
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
2011-03-01
2025-05-01
Active, not recruiting
43
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
2011-07-01
2017-06-14
Completed
1,232

Rows per page:

1–100 of 102

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" #1 sponsor was "Hoffmann-La Roche" with 19 trials, followed by "Italian Sarcoma Group" with 14 trials sponsored, "Fondazione del Piemonte per l'Oncologia" with 13 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Incyte Corporation" with 6 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 35 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "PharmaMar" with 4 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 3 trials as a collaborator and "AstraZeneca" with 2 trials as a collaborator. Other collaborators include 47 different institutions and companies that were collaborators in the rest 53 trials.
Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 19Hoffmann-La Roche: 19Italian Sarcoma Group: 14Italian Sarcoma Group: 14Fondazione delPiemonte perl'Oncologia: 13Fondazione delPiemonte perl'Oncologia: 13Eli Lilly and Company: 6Eli Lilly and Company: 6Incyte Corporation: 6Incyte Corporation: 6EMD Serono Research &Development Institute,Inc.: 4EMD Serono Research &Development Institute,Inc.: 4National CancerInstitute, Naples: 4National CancerInstitute, Naples: 4Pfizer: 4Pfizer: 4Fondazione ItalianaLinfomi ONLUS: 2Fondazione ItalianaLinfomi ONLUS: 2Genentech, Inc.: 2Genentech, Inc.: 2

Created with Highcharts 11.1.0Top CollaboratorsMerck KGaA,Darmstadt, Germany: 5Merck KGaA,Darmstadt, Germany: 5PharmaMar: 4PharmaMar: 4Hoffmann-La Roche: 3Hoffmann-La Roche: 3Mario Negri Institute forPharmacologicalResearch: 3Mario Negri Institute forPharmacologicalResearch: 3AstraZeneca: 2AstraZeneca: 2BeiGene, Ltd.: 2BeiGene, Ltd.: 2Bristol-Myers Squibb: 2Bristol-Myers Squibb: 2Clinical ResearchTechnology S.r.l.: 2Clinical ResearchTechnology S.r.l.: 2Merck Sharp & Dohme LLC: 2Merck Sharp & Dohme LLC: 2ADVANTIS MEDICALIMAGING SINGLEMEMBER PC: 1ADVANTIS MEDICALIMAGING SINGLEMEMBER PC: 1

Clinical Trials Conditions at Fondazione del Piemonte per l'Oncologia IRCC Candiolo


According to Clinical.Site data, the most researched conditions in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are "Breast Cancer" (8 trials), "Metastatic Colorectal Cancer" (5 trials), "Colorectal Cancer" (4 trials), "Melanoma" (3 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" in a lesser frequency.

Clinical Trials Intervention Types at Fondazione del Piemonte per l'Oncologia IRCC Candiolo


Most popular intervention types in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are "Drug" (81 trials), "Other" (10 trials), "Diagnostic Test" (7 trials), "Biological" (5 trials) and "Radiation" (2 trials). Other intervention types were less common.
The name of intervention was led by "Paclitaxel" (12 trials), "Placebo" (8 trials), "Trastuzumab" (8 trials), "Atezolizumab" (7 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

Clinical Trials Genders at Fondazione del Piemonte per l'Oncologia IRCC Candiolo


The vast majority of trials in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are 87 trials for "All" genders, 11 trials for "Female" genders and 4 trials for "Male" genders.

Clinical Trials Status at Fondazione del Piemonte per l'Oncologia IRCC Candiolo


Currently, there are NaN active trials in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo". undefined are not yet recruiting, 27 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Fondazione del Piemonte per l'Oncologia IRCC Candiolo, undefined suspended trials, and 6 terminated clinical trials to date.
Out of the total trials that were conducted in Fondazione del Piemonte per l'Oncologia IRCC Candiolo, 10 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 41Phase 3: 41Phase 2: 32Phase 2: 32Phase 1: 10Phase 1: 10Phase 4: 4Phase 4: 4Not Applicable: 2Not Applicable: 2

Created with Highcharts 11.1.0Trials StatusCompleted: 34Completed: 34Recruiting: 27Recruiting: 27Active, not recruiting: 24Active, not recruiting: 24Unknown status: 8Unknown status: 8Terminated: 6Terminated: 6Withdrawn: 3Withdrawn: 3

Departments of Fondazione del Piemonte per l'Oncologia IRCC Candiolo


Fondazione del Piemonte per l'Oncologia IRCC Candiolo has several departments that took part in Clinical trials: "I.R.C.C. - Unit of Medical Oncology" - 8 trials, "IRCC Onco-Ematologia" - 2 trials
Departments List
Total Rows: 2